Craig A Metz, PhD, Co-Founder & Chief Executive Officer
Dr. Craig Metz has over 45 years of pharmaceutical industry experience and is a former Vice President of US Regulatory Affairs at GlaxoSmithKline, where he led the regulatory group responsible for GSK’s entire early drug development portfolio. In this capacity, Craig provided oversight and review for 60-80 initial IND submissions each year, many of which were in therapeutic settings involving rare disorders or orphan diseases with significant unmet medical need.
Dr. Patrick Anthony Akkari, PhD, Co-Founder & Chief Scientific Officer
Recruited from the pharmaceutical industry in North Carolina to lead complimentary positions in Perth within Murdoch University and The Perron Institute. In this dual capacity, Anthony has established a genetics drug discovery laboratory and identified a path to more efficiently move potential drug candidates from that laboratory to the clinic. As Head of Motor Neuron Disease Genetics and Therapeutics Research at The Perron Institute and a Professor of Industrial Pharmacogenetics at Murdoch University, Anthony has been instrumental in establishing the foundational science and drug discovery pipeline that comprises the therapeutic development pipeline for Black Swan Pharmaceuticals.
Julian Arbuckle, Co-Founder & Chief Business Officer
Julian Arbuckle has worked in the life sciences sector for over 25 years and has significant knowledge of the research and development process gained by working within both blue-chip pharmaceutical and start-up biotechnology companies.
During his time in the industry he has gained significant experience in leading drug development programs and providing specialist scientific consulting advice to sponsors working on long-term prevention trials in the CNS disease area. He has also initiated, and led, several industry/academic collaborations working primarily in the field of precision medicine. Julian also extensive experience of business development, alliance management and commercial aspects of the drug development business.
Having provided scientific consultancy for many different clients within the pharmaceutical and biotechnology industries, Julian has extensive knowledge of how these organizations operate, and gained significant insight into ways to expedite the delivery and execution of specialist drug development programs.
In addition to his role as CBO at Black Swan Pharmaceuticals, Julian is also the President of the Industry Pharmacogenomics Working Group (I-PWG); the I-PWG is an industry-led scientific forum which has representation from all the major pharmaceutical companies with a remit to engage pre-competitively to address emerging issues related to precision medicine.
Julian has a BSc (Hons) in Biological Sciences from Leicester University (UK).